Recurrence of vertebral fracture with cyclical etidronate therapy in osteoporosis: Histomorphometry and X-ray microanalysis evaluation

Journal of Bone and Mineral Research

Volumn 14, Issue 2, 1999, Pages 198-205

  Thomas, Thierry ^a   Barou, Odile ^a   Vico, Laurence ^a   Alexandre, Christian ^a,b   Lafage Proust, Marie Helene ^a  

^a UNIVERSITÉ JEAN MONNET   (France)

^b UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; ETIDRONIC ACID;

ADULT; ARTICLE; BONE MASS; BONE MINERAL; BONE STRENGTH; CLINICAL ARTICLE; CRYSTALLIZATION; FEMALE; HUMAN; MALE; MINERALIZATION; MORPHOMETRICS; OSTEOPOROSIS; PROSPECTIVE STUDY; RECURRENT DISEASE; TRABECULAR BONE; VERTEBRA FRACTURE; X RAY MICROANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY; BONE DENSITY; BONE REMODELING; CALCIUM; ELECTRON PROBE MICROANALYSIS; ETIDRONIC ACID; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS; PHOSPHORUS; PROSPECTIVE STUDIES; RECURRENCE; SPINAL FRACTURES;

EID: 0032943077     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.1999.14.2.198     Document Type: Article

References (52)

1. Melton LJ, Atkinson EJ, O'Fallon WM, Wahner HW, Riggs BL 1993 Long-term fracture risk prediction by bone mineral density assessed at different skeletal sites. J Bone Miner Res 8:1227-1233.
2. Riggs BL, Hogson SF, O'Fallon WM, Chao EYS, Wahner HW, Muhs JM, Cedel SL, Melton LJ III 1990 Effects of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 322:802-809.
3. Turner CH, Akhter MP, Heaney RP 1992 The effects of fluoridated water on bone strength. J Orthop Res 10:581-587.
4. Sogaard CH, Mosekilde E, Richards A, Mosekilde L 1994 Marked decrease in trabecular bone quality after five years of sodium-fluoride therapy assessed by biomechanical testing of iliac crest bone biopsies in osteoporotic patients. Bone 15:393-399.
5. Lafage MH, Balena R, Battle MA, Shea M, Seedor JG, Klein H, Hayes WC, Rodan G 1995 Comparison of alendronate and sodium fluoride effects on cancellous and cortical bone in minipigs. J Clin Invest 95:2127-2133.
6. Libanati C, Lau KW, Baylink D 1996 Fluoride therapy for osteoporosis. In: Marcus R, Feldman D, Kelsey J (eds.) Osteoporosis. Academic Press, San Diego, CA, U.S.A., pp. 1259-1277.
7. Pak CYC, Sakhaee K, Adams-Huet B, Piziak V, Peterson RD, Poindexter JR 1995 Treatment of postmenopausal osteoporosis with slow-release sodium fluoride-final report of a randomized control group. Ann Intern Med 123:401-408.
8. Storm T, Thamsborg G, Steiniche T, Genant HK, Sorensen OH 1990 Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 322:1265-1271.
9. Watts NB, Harris ST, Genant HK, Wasnich RD, Miller PD, Jackson RD, Licata AA, Ross P, Woodson GC, Yanover MJ, Mysim J, Kohse L, Rao MB, Steiger P, Richmond B, Chesnut CH 1990 Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 323:73-79.
10. Harris ST, Watts NB, Jackson RD, Genant HK, Wasnich RD, Ross P, Miller PD, Licata AA, Chesnut CH III 1994 Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: Three years of blinded therapy followed by one year of open therapy. Am J Med 95:557-567.
11. Wimalawansa SJ 1995 Combined therapy with estrogen and etidronate has an additive effect on bone mineral density in the hip and vertebrae: Four-year randomized study. Am J Med 99:36-42.
12. Thomas T, Lafage MH, Alexandre C 1995 Atypical osteomalacia after 2 year etidronate intermittent cyclic administration in osteoporosis. J Rheumatol 22:2183-2185.
13. Francis MD, Russell RGG, Fleisch H 1969 Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in vivo. Science 165:1264-1266.
14. Fogelman I, Smith L, Mazess R, Wilson MA, Bevan JA 1986 Absorption of oral diphosphonate in normal subjects. Clin Endocrinol (Oxf) 24:57-62.
15. Civitelli R, Gonnelli S, Zacchei F, Bigazzi S, Vattimo A, Avioli LV, Gennari C 1988 Bone turnover in postmenopausal osteoporosis. J Clin Invest 82:1268-1274.
16. Paparella P, Giogino R, Mancuso S, the multicenter study group 1995 Oral continuous clodronate in the prevention of early postmenopausal bone loss. Curr Ther Res 56:134-143.
17. Chesnut IIICH, Bell NH, Clark GS, Drinkwater BL, English SC, Johnston CC Jr, Notelovitz M, Rosen C, Cain DF, Flessland KA, Malinak NJS 1997 Hormone replacement therapy in postmenopausal women: Urinary N-telopeptide of type I collagen monitors therapeutic effects and predicts response of bone mineral density. Am J Med 102:29-37.
18. Chappard D, Alexandre C, Camps M, Montheard JP, Riffat G 1983 Embedding iliac bone biopsies at low temperature using glycol and methyl methacrylate. Stain Technol 58:299-308.
19. Chappard D, Alexandre C, Riffat G 1983 Histochemical identification of osteoclasts: review of current methods and reappraisal of a simple procedure for routine diagnosis on undecalcified human iliac bone biopsies. Basic Appl Histochem 27:75-85.
20. Cohen-Solal ME, Mei-Shu S, Lundy MW, Parfitt AM 1991 A new method for measuring cancellous bone erosion depth: Application to the cellular mechanisms of bone loss in post menopausal osteoporosis. J Bone Miner Res 6:1331-1338.
21. Parfitt AM, Mathews CHE, Villanueva AR, Kleerekoper M, Frame B, Rao DS 1983 Relationship between surface, volume, and thickness of iliac trabecular bone in aging and in osteoporosis: Implications for the microanatomic and cellular mechanism of bone loss. J Clin Invest 72:1396-1409.
22. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA. Malluche H, Meunier PJ, Ott SM, Recker RR 1987 Bone histomorphometry: Standardization of nomenclature, symbols, and units. J Bone Miner Res 2:595-610.
23. Dubost JM, Palle S, Alexandre C, Lafage MH 1996 X-ray micro-analysis of bone mineral components - Quantitative analysis of different bone compartments. J Trace Microprobe Tech 14:751-761.
24. Ott SM, Woodson GC, Huffer WE, Miller PD, Watts NB 1994 Bone histomorphometry changes after cyclic therapy with phosphate and etidronate disodium in women with postmenopausal osteoporosis. J Clin Endocrinol Metab 78:968-972.
25. de Vernejoul MC, Kuntz D, Miravet L, Goutallier D, Rickewaert A 1981 Bone histomorphometry reproducibility in normal patients. Calcif Tissue Int 33:369-374.
26. Bonnekamp PM, van der Wee-Pals LJA, van Wijk-van Lennep MML, Thesing CW, Bijvoet OLM 1986 Two mode of action of bisphosphonates on osteoclastic resorption of mineralized matrix. Bone Miner 1:27-39.
27. Parfitt AM, Mundy GR, Roodman GD, Hughes DE, Boyce BF 1996 A new model for the regulation of bone resorption, with particular reference to the effects of bisphosphonates. J Bone Miner Res 11:150-159.
28. Hughes DE, Wright KR, Uy LH, Sasaki A, Yoneda T, Roodman GD, Mundy GR, Boyce BF 1995 Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 10:1478-1487.
29. 3H-etidronate in rat and mouse bones. Bone 19:281-290.
30. Azuma Y, Sato H, Oue Y, Okabe K, Ohta T, Tsuchimoto M, Kiyoki M 1995 Alendronate distributed on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemia models. Bone 16:235-247.
31. Fleisch H, Russell RGG, Bisaz S, Muhlbauer RC, Williams DA 1970 The inhibitory effect of phosphonates on bone formation of calcium phosphate crystals in vitro and on aortic and kydney calcification in vivo. Eur J Clin Invest 1:12-18.
32. Francis MD 1969 The inhibition of calcium hydroxyapatite crystal growth by polyphosphonates and polyphosphates. Calcif Tissue Res 3:151-162.
33. Amprino R, Engstrom A 1952 Studies of x-ray absorption and diffraction of bone tissue. Acta Anal (Basel) 75:1-22.
34. Meunier PJ, Boivin G 1997 Bone mineral density reflects bone mass but also the degree of mineralization of bone: Therapeutic implications. Bone 21:373-377.
35. Katsumata T, Nakamura T, Ohnishi H, Sakurama T 1995 Intermittent cyclical etidronate treatment maintains the mass, structure and the mechanical property of bone in ovariectomized rats. J Bone Miner Res 10:921-931.
36. Einhorn TA 1992 Bone strength: The bottom line. Calcif Tissue Int 51:333-339.
37. Parfitt AM 1984 Age-related structural changes in trabecular and cortical bone: Cellular mechanisms and biochemical consequences. Calcif Tissue Int 36:123-128.
38. Riggs BL, Melton LJ III, O'Fallon WM 1996 Drug therapy for vertebral fractures in osteoporosis. Bone 18:197S-201S.
39. Riggs BL, Melton LJ III 1986 Medical progress series: Involutional osteoporosis. N Engl J Med 314:1676-1686.
40. Pouilles JM, Tremollieres F, Roux C, Sebert JL, Alexandre C, Goldberg D, Treves R, Khalifa P, Duntze P, Horlait S, Delmas PD, Kuntz D 1997 Effects of cyclical etidronate therapy on bone loss in early postmenopausal women who are not undergoing hormonal replacement therapy. Osteoporos Int 7:213-218.
41. Meunier PJ, Confavreux E, Tupinon I, Hardouin C, Delmas PD, Balena R 1997 Prevention of early postmenopausal bone loss with cyclical etidronate therapy (a double-blind, placebo-controlled study and 1-year follow-up). J Clin Endocrinol Metab 82:2784-2791.
42. Herd RJM, Balena R, Blake GM, Ryan PJ, Fogelman I 1997 The prevention of early postmenopausal bone loss by cyclical etidronate therapy - A 2-year, double-blind, placebo-controlled study. Am J Med 103:92-99.
43. Lyritis GP, Tsakalakos N, Paspati I, Skarantavos Gr Galanos A, Androulakis C 1997 The effect of a modified etidronate cyclical regimen on postmenopausal osteoporosis: A four-year study. Clin Rheumatol 16:354-360.
44. Bettica P, Bevilacqua M, Vago T, Masino M, Cucinotta E, Norbiato G 1997 Short-term variations in bone remodeling biochemical markers: Cyclical etidronate and alendronate effects compared. J Clin Endocrinol Metab 82:3034-3039.
45. Montessori MLM, Scheele WH, Netelenbos JC, Kerkhoff JF, Bakker K 1997 The use of etidronate and calcium versus calcium alone in the treatment of postmenopausal osteopenia: Results of three years of treatment. Osteoporos Int 7:52-58.
46. Storm T, Steiniche T, Thamsborg G, Meisen F 1993 Changes in bone histomorphometry after long-term treatment with intermittent cyclic etidronate for postmenopausal osteoporosis. J Bone Miner Res 8:199-208.
47. Hodsman AB 1989 Effects of cyclical therapy for osteoporosis using an oral regimen of inorganic phosphate and sodium etidronate: A clinical and bone histomorphometric study. Bone Miner 5:201-212.
48. Heaney RP 1994 The bone-remodeling transient: Implications for the interpretation of clinical studies of bone mass change. J Bone Miner Res 10:1515-1523.
49. Khosla S 1997 Idiopathic osteoporosis, is the osteoblast to blame? J Clin Endocrinol Metab 82:2792-2794.
50. Geusens P, Vanhoof J, Raus J, Dequeker J, Nijs J, Joly J 1996 Treatment with etidronate for men with idiopathic osteoporosis. Ann Rheum Dis 55:280.
51. Anderson FH, Francis RM, Bishop JC, Rawlings DJ 1997 Effect of intermittent cyclical disodium etidronate therapy on bone mineral densiy in men with vertebral fractures. Age Ageing 26:359-365.
52. Orme SM, Simpson M, Stewart SP, Oldroyd B, Westmacott CF, Smith MA, Belchetz PE 1994 Comparison of changes in bone mineral in idiopathic and secondary osteoporosis following therapy with clinical disodium etidronate and high dose calcium supplementation. Clin Endocrinol 41:245-250.